Biogen Inc.

Biogen’s 2026 10-Q, filed April 29, 2026, presents a discussion of market risks and the instruments used to manage them, but notably omits the quantitative data necessary for common forensic accounting models. The MD&A, under Item 7, details exposure to “volatility in foreign currency exchange rates, interest rate movements and equity price exposure,” alongside “changes in economic conditions” stemming from geopolitical conflicts. The company employs various derivative instruments such as foreign currency forward contracts and interest rate swaps to mitigate these exposures, a common practice that introduces its own layer of financial complexity.

The filing does not provide the data points required to calculate key forensic metrics. Beneish’s M-Score, a 1999 eight-ratio earnings-manipulation detector, is not available. Similarly, Altman’s Z″, a 1968 bankruptcy-distress index, remains uncalculated. Piotroski’s F-Score, a 2000 nine-point fundamental strength scan, is also absent. Finally, the Fog Index, a 1952 readability score where 12 equals newspaper clarity and 18+ suggests obfuscation, is not provided, making a quantitative assessment of the filing’s linguistic complexity impossible.

The MD&A’s Item 7, “Quantitative and Qualitative Disclosures About Market Risk,” highlights the company’s proactive stance on financial risk management. Beyond currency and interest rate fluctuations, the filing specifically mentions economic changes “as a result of the conflict between Russia and Ukraine and the military conflict in the Middle East.” This explicit acknowledgment of geopolitical factors underscores the interconnectedness of global events and corporate financial health, with derivatives serving as the primary tool for hedging these broad, systemic risks.

This reading of the 10-Q is limited by the absence of calculated forensic scores. While the filing outlines Biogen’s approach to managing market risks and its reliance on forward-looking statements, it does not offer the specific quantitative signals that models like Beneish, Altman, or Piotroski provide regarding potential accounting anomalies, financial distress, or fundamental strength. The filing describes the company’s risk management framework but does not, in itself, provide the data to assess its effectiveness or the underlying financial health through these established forensic lenses.